HEPATITIS C DRUGS MARKET ANALYSIS

Hepatitis C Drugs Market, By Drug Class (NS3/4A Protease Inhibitors, NS5A Inhibitors, NS5B Polymerase Inhibitors, Combination Drugs, others), By Route of Administration (Oral Drugs, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

New product launches:

On December 7, 2021, Zydus Cadila, a pharmaceutical company based in India, launched a generic version of Gilead Sciences’ Hepatitis C drug Sofosbuvir in India under the brand name ‘SoviHep’.
On September 24, 2018, Gilead Sciences, Inc., a pharmaceutical company, announced the launch of a generic version of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for hepatitis C treatment.

Acquisition and partnerships:

On May 31, 2023, The Institute of Drug Technology (Farmanguinhos/Fiocruz) signed a new partnership for the technological transfer of the drug Daclatasvir. This formalization allows expanding access to the drug deemed strategic for the Brazilian Unified Health System (SUS)

Hepatitis C Drugs Market Report Snapshots